FDA: Enzon's Abelcet makes unsubstantiated superiority claims

Share this article:
A flash card for Enzon's Abelcet makes unsubstantiated superiority claims and overstates its efficacy, the FDA says. A warning letter says the claims raise concerns because they suggest it is more effective than  demonstrated and encourage its use before other options, even though it is a second-line agent.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.

Email Newsletters